Oramed Pharmaceuticals (ORMP) Accounts Payables (2011 - 2026)

Oramed Pharmaceuticals has reported Accounts Payables for 16 years, with the latest figure at $8.5 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 1574.07% year-over-year to $8.5 million; the trailing twelve-month figure through Mar 2026 stood at $8.5 million (up 1574.07% YoY), and the FY2025 full-year result was $6.2 million, up 685.93% from the prior year.
• Accounts Payables for Q1 2026 stood at $8.5 million, up from $6.2 million in the prior quarter.
• The five-year high for Accounts Payables was $8.5 million in Q1 2026, with the low at $509000.0 in Q1 2025.
• Historically, Accounts Payables has averaged $3.2 million across 5 years, with a median of $3.5 million in 2022.
• Annual changes were most pronounced in 2023 — Accounts Payables sank 86.75% — and 2026, when it jumped 1574.07%.
• Oramed Pharmaceuticals' Accounts Payables stood at $4.2 million in 2022, then slumped by 86.75% to $551000.0 in 2023, then surged by 43.19% to $789000.0 in 2024, then jumped by 685.93% to $6.2 million in 2025, then soared by 37.41% to $8.5 million in 2026.
• The last three Accounts Payables figures came in at $8.5 million (Q1 2026), $6.2 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.